Funding Opportunities

Winship researchers receive funding through a variety of awards and grants. View a selection of federal and private funding opportunities for which Winship researchers may be eligible to apply.

Winship Invest$

Winship Invest$ is a peer-reviewed program providing pilot funding for novel, innovative cancer research projects. The summer 2017 opportunity is focused on the growth and development of Winship’s four research programs, in addition to breast cancer-related research. Proposals with one-year budgets of up to $50,000 may be considered. The highest scored proposal across those selected for funding will receive the Fadlo R. Khuri Translational Research Scholar Award in recognition of outstanding and transformative science.


  1. Pilot projects will be awarded to active Winship members.
  2. Winship members will qualify for only one pilot project grant in a given year and may not submit more than one proposal through this RFP.
  3. Salary support for the principal investigator is not allowed except for junior faculty at the rank of Assistant Professor and below.
  4. All proposals must include a clear plan for subsequent extramural grant submissions as a result of the work proposed.
  5. Data Management - Proposals must include a plan to maintain research data in Redcap or other secure data management system (if relevant) with quality control and stored on the Emory system with back-up and potential for data sharing. Consultation for data sharing plans with the Winship Research Informatics Shared Resource are recommended.
  6. Clinical Research proposals can only be submitted by MDs, MD/PhDs, or RN/PhDs and must include:
    • A Human Subjects Research document
    • Winship CTRC Application
    • Clinical Protocol and Informed Consent Form
    • A plan to maintain clinical research data in OnCore or through the support of the Winship Informatics Shared Resource
    • All clinical research awardees are expected to follow clinical research guidelines set by Emory IRB, Winship Clinical Trials SOPs and the Winship Clinical and Translational Research Committee, and must satisfy clinical research training requirements.
  7. Proposals which include in vivo studies must include a:
    • Section addressing Vertebrate Animals research;
    • IACUC protocol (draft to be submitted or IACUC-approved protocol)
  8. Members receiving funding are expected to submit annual progress reports.

Letter of Intent Due Date: August 4, 2017

Application Due Date: October 6, 2017

Anticipated Start Date: January 1, 2018

International Myeloma Foundation Brian D. Novis Research Award

The International Myeloma Foundation’s Brian D. Novis Research Award are awarded annually to researchers doing work in the field of multiple myeloma and related disorders including smoldering myeloma, MGUS (monoclonal gammopathy of undetermined significance) as well as immunoglobulin derived amyloidosis. This year's awards will be $50,000 each for the junior grant and $80,000 for the senior grant.

Junior Grants
The qualifications for a candidate for the Brian D. Novis Junior Research Award include the following:

  • Completed postdoctoral studies or clinical fellowships no later than August 1 of the application year.
  • Ability to devote a minimum of 50% of his or her time to the research project during the Award year.
  • Ability to provide a completed application with evidence of a meritorious research project.
  • NIH, other foundations or similar funding agencies.

Senior Grants
These awards are targeted to established investigators with a track record in myeloma or related disorders, and are designed for projects which represent a different focus, direction, or area of research from those in which they are currently funded. In most cases, these awards will be for pilot projects to obtain sufficient funding for larger applications from NIH or similar larger funding agencies.

The qualifications for a candidate for the Brian D. Novis Senior Research Award include the following:

  • Ability to provide a completed application with evidence of a meritorious research project.
  • NIH, other foundations or similar funding agencies.

Application Due Date: August 1, 2017

NCI R01: HIV/AIDS and the Tumor Niche

The National Cancer Institute of the National Institutes of Health is seeking R01 applications that address the role of the tumor niche or microenvironment in the risks, development, progression, diagnosis, and treatment of cancer observed in individuals with an underlying HIV infection or Acquired Immune Deficiency Syndrome (AIDS).

Application Due Date: August 7, 2017, by 5:00 PM local time of applicant organization

Fanconi Anemia Research Fund Grants

The Fanconi Anemia Research Fund seeks to improve the lives of individuals with Fanconi anemia through research that focuses on the rapid discovery and development of therapies or strategies that treat, control, or cure Fanconi anemia.

Fanconi is interested in supporting interdisciplinary and translational research efforts that effectively address one or more of the following priorities:
  • To understand how alteration of the Fanconi anemia genes and their products lead to the clinical manifestations of Fanconi anemia.
  • To determine the causes of bone marrow failure, myelodysplasia and leukemia in individuals with Fanconi anemia, and to develop strategies to prevent, treat, and cure these disorders.
  • To define the pathogenesis of Fanconi anemia-associated cancers, and to develop strategies for prevention, early detection, treatment and cure.
  • To identify practical and proactive management strategies that families and persons with Fanconi anemia can use to maintain a high quality of life.
  • To support the creation of shared resources, databases, and technologies for the international Fanconi anemia research community.

A Letter of Intent (LOI) is required for research funding consideration. The LOI is limited to one page and must include (1) Specific Aims, (2) Lay Abstract, (3) Total Funds Requested and (4) Translatable Applicability. A submitted LOI longer than one page will be returned.

Letter of Intent Due Date: October 13, 2017
Investigator Informed of Decision: November 3, 2017
Grant Submission Due Date: February 2, 2018
Investigator Informed of Decision: June 29, 2018
Earliest Project Start Date: August 1, 2018

Oral Anticancer Agents: Utilization, Adherence, and Health Care Delivery

The Behavioral Research Program, Epidemiology and Genomics Research Program, and Healthcare Delivery Research Program of the National Cancer Institute’s Division of Cancer Control and Population Sciences have collaborated on the release of a program announcement to study the utilization, adherence, and delivery of oral anticancer agents.  Specifically, this program announcement encourages research grant applications to:

  1. Assess and describe the current state of oral anticancer medication utilization, delivery, and adherence; 
  2. Identify structural, systemic, and psychosocial barriers to adherence; and 
  3. Develop models and strategies to improve safe and effective delivery of these agents so that clinical outcomes are optimized.   

PA-17-060 (R01)
PA-17-061 (R21)

Standard application due dates apply.

Cascade Link  TOP